Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in
the days of COVID-19 pandemic
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid leukemia (CML), and currently in patients with CML in chronic phase (CML-CP) the first-line treatment is based on BCR-ABL targeted therapy with TKIs . Although generally well tolerated, all BCR-ABL TKIs can be associated with hematologic and non-hematologic toxicities . Most of the patients with CML-CP continue receiving TKIs, unless there is lack of optimal response and/or serious toxicities.